| Literature DB >> 31484533 |
Hongzeng Wu1, Jinming Zhang1, Ruoheng Dai2, Jianfa Xu1, Helin Feng3.
Abstract
BACKGROUND: Osteosarcoma is aggressive and prognostic biomarkers are important to predict the outcomes of surgery and chemotherapy. Here, we investigated the potential of transferrin receptor-1 (TfR1) and vascular endothelial growth factor (VEGF) as prognostic markers of osteosarcoma.Entities:
Keywords: Osteosarcoma; Prognosis; Transferrin receptor-1; VEGF
Mesh:
Substances:
Year: 2019 PMID: 31484533 PMCID: PMC6727552 DOI: 10.1186/s13018-019-1301-z
Source DB: PubMed Journal: J Orthop Surg Res ISSN: 1749-799X Impact factor: 2.359
Fig. 1Representative immunohistochemical staining of TfR1 and VEGF. a High expression of TfR1 in OS. c Moderate expression of TfR1 in OS. e Low expression of TfR1 in OS. b High expression of VEGF in OS. d Moderate expression of VEGF in OS. f Low expression of VEGF in OS. The cells with positive expression were stained brown
Clinicopathological variables and the expression of TfR1 and VEGF
| TfR1 |
| VEGF |
| |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Low(%) | Mild(%) | High(%) | Low(%) | Mild(%) | High(%) | |||||
| Sex | Female | 25 | 3(12.0) | 10(40.0) | 12(48.0) | 0.332 | 5(20.0) | 11(44.0) | 9(36.0) | 0.405 |
| Male | 28 | 8(28.6) | 9(32.1) | 11(39.3) | 5(17.8) | 8(28.6) | 15(53.6) | |||
| Age | ≥ 20 years | 18 | 4(22.2) | 4(22.2) | 10(55.6) | 0.306 | 3(16.7) | 9(50.0) | 6(33.3) | 0.293 |
| < 20 years | 35 | 7(20.0) | 15(42.9) | 13(37.1) | 7(20.0) | 10(28.6) | 18(51.4) | |||
| Tumor size | < 5 cm | 27 | 6(22.2) | 10(37.0) | 11(40.8) | 0.919 | 6(22.2) | 10(37.0) | 11(40.7) | 0.741 |
| ≥ 5 cm | 26 | 5(19.2) | 9(34.6) | 12(46.2) | 4(15.4) | 9(34.6) | 13(50.0) | |||
| Histologic grade* | I | 15 | 4(26.7) | 8(53.3) | 3(20.0) | 0.04 | 4(26.7) | 9(60.0) | 2(13.3) | 0.02 |
| II | 25 | 5(20.0) | 10(40.0) | 10(40.0) | 5(20.0) | 8(32.0) | 12(48.0) | |||
| III | 13 | 2(15.4) | 1(7.7) | 10(76.9) | 1(7.7) | 2(15.4) | 10(76.9) | |||
| Distant metastasis* | Yes | 23 | 1(4.2) | 11(47.8) | 11(47.8) | 0.029 | 1(4.4) | 13(56.5) | 9(39.1) | 0.008 |
| No | 30 | 10(33.3) | 8(26.7) | 12(40.0) | 9(30.0) | 6(20.0) | 15(50.0) | |||
| Enneking staging* | I | 12 | 8 (66.7) | 3 (25.0) | 7(36.9) | < 0.001 | 6(50.0) | 4(33.3) | 2(16.7) | 0.004 |
| II | 19 | 2 (10.5) | 10(52.6) | 21(43.8%) | 2(10.5) | 10(52.6) | 7(36.9) | |||
| III | 22 | 1 (4.5) | 6 (27.3) | 15 (68.2) | 2(9.1) | 5(22.7) | 15(68.2) | |||
Pearson’s chi-squared test was used. *P < 0.05
The correlation of TfR1 and VEGF expression
| Characteristics | TfR1 | |||||
|---|---|---|---|---|---|---|
| Low(%) | Mild(%) | High(%) | ||||
| VEGF* | Low | 10 | 6(11.3) | 3(5.7) | 1(1.9) | = 0.001 |
| Mild | 19 | 2(3.7) | 10(18.9) | 7(13.2) | ||
| High | 24 | 3(5.7) | 6(11.3) | 15(28.3) | ||
| 53 | 11 | 19 | 23 | |||
Spearman-rho test was used. *P < 0.05
Clinicopathological factors associated with overall survival based on univariate Cox proportional regression analysis
| Characteristics | Overall survival |
| |||
|---|---|---|---|---|---|
| HR | 95% CI | ||||
| Sex | Female | 25 | 1 | 0.837 | |
| Male | 28 | 1.064 | 0.590–1.919 | ||
| Age | ≥ 20 years | 18 | 1 | 0.777 | |
| < 20 years | 35 | 1.093 | 0.591–2.022 | ||
| Tumor size | < 5 cm | 27 | 1 | 0.940 | |
| ≥ 5 cm | 26 | 1.024 | 0.556–1.884 | ||
| Histologic grade* | I | 15 | 1 | 0.412 | |
| II | 25 | 1.267 | 0.634–2.534 | 0.503 | |
| III | 13 | 1.738 | 0.771–3.917 | 0.183 | |
| Distant metastasis* | Yes | 23 | 1 | < 0.001 | |
| No | 30 | 0.161 | 0.073–0.356 | ||
| Enneking staging* | I | 12 | 1 | < 0.001 | |
| II | 19 | 8.605 | 2.942–25.169 | ||
| III | 22 | 26.039 | 7.679–88.293 | ||
| TfR1* | Low | 11 | 1 | < 0.001 | |
| Moderate | 19 | 0.158 | 0.063–0.398 | ||
| High | 23 | 0.300 | 0.143–0.629 | ||
| VEGF* | Low | 10 | 1 | 0.021 | |
| Moderate | 19 | 0.114 | 0.043–0.303 | ||
| High | 24 | 0.422 | 0.202–0.880 | ||
HR, hazard ratio; 95% CI, 95% confidence interval. *P < 0.05
Fig. 2Overall survival curves of patients with OS. a Association of overall survival with distant metastasis. b Association of overall survival with TfR1 expression. c Association of overall survival with VEGF expression. d Association of overall survival with clinical stage
Clinicopathological factors associated with overall survival based on multivariate Cox regression analysis
| Overall survival | |||
|---|---|---|---|
| HR | 95% CI |
| |
| Enneking stage | 4.622 | 2.541–8.406 | < 0.001 |
| TfR1 | 2.514 | 1.445–4.372 | 0.001 |
| VEGF | 2.882 | 1.203–8.217 | 0.002 |
HR, hazard ratio; 95% CI, 95% confidence interval. *P < 0.05